EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC 4.0

Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B

Heechul Nam iD, Ji Won Han, Soon Kyu Lee iD, Hyun Yang, Hae Lim Lee, Pil Soo Sung iD, Myeong Jun Song iD, Jung Hyun Kwon iD, Jeong Won Jang iD, U-Im Chang, Chang Wook Kim, Soon Woo Nam und 5 weitere

Journal of Gastroenterology and Hepatology · 2024

DOI: 10.1111/jgh.16593 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of Gastroenterology and Hepatology, 2024. Verfasst von Heechul Nam und 16 weiteren Autor:innen. Beteiligte Einrichtung: The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Tenofovir, Hepatitis B, Chronic, Glomerular Filtration Rate, Drug Substitution. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background and Aim Our study evaluated the outcomes of switching from tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) in patients with chronic hepatitis B (CHB). We assessed viral and biochemical responses as well as changes in the estimated glomerular filtration rate (eGFR) and bone mineral density (BMD).

Methods

This retrospective multicenter study included CHB patients who achieved virologic response (VR) (HBV DNA < 20 IU/mL) while on TDF and were subsequently switched to TAF between April 2018 and October 2021.

Results

This study included 309 patients with a median age of 59 years, and 42.1% were male. The mean duration of TDF and TAF administration were 54.0 and 37.5 months, respectively. All patients maintained VR after switching to TAF. Alanine aminotransferase (ALT) normalization rate significantly increased 6 months after switching (74.8%–83.5%; P = 0.008). Adjusted eGFR significantly improved at 6 months (+5.55 ± 10.52 mL/min/1.73 m 2 ; P < 0.001) and 12 months (+6.02 ± 10.70 mL/min/1.73 m 2 ; P < 0.001) after switching. In the subgroup of patients with renal impairment (eGFR < 60 mL/min/1.73 m 2 ), significant improvement in renal function was observed at 6 months (+0.6 ± 10.5 mL/min/1.73 m 2 ; P < 0.001) and 12 months (+1.0 ± 10.7 mL/min/1.73 m 2 ; P < 0.001) after switching to TAF. In patients with osteoporosis ( n = 182), switching to TAF resulted in significant improvement in spine and hip BMD at 12 months, with increases of 9.7% (95% CI: 7.0–12.5) and 9.4% (95% CI: 7.0–11.8), respectively.

Conclusion

In this real‐world study, switching to TAF was effective and safe in patients, with notable improvements in ALT levels, renal function, and BMD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

TenofovirHepatitis B, ChronicGlomerular Filtration RateDrug SubstitutionBone DensityAlanineAntiviral AgentsHumansMaleMiddle AgedFemaleRetrospective StudiesTreatment OutcomeAdenineAgedAdult

Stichwörter der Autor:innen

bone mineral densitychronic hepatitis Bglomerular filtration ratetenofovir alafenamidetenofovir disoproxil fumarate

Substanzen

Tenofovirtenofovir alafenamideAlanineAntiviral AgentsAdenine

Autor:innen und Institutionen

  • The Catholic University Liver Research Center, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Division of Hepatology, Department of Internal Medicine, Uijeongbu St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon-si, Republic of Korea.
  • Division of Hepatology, Department of Internal Medicine, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Division of Hepatology, Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon, Republic of Korea.
  • Division of Hepatology, Department of Internal Medicine, Eunpyeong St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
  • Division of Hepatology, Department of Internal Medicine, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Bucheon-si, Republic of Korea.

ORCID-Profile: Heechul Nam, Soon Kyu Lee, Pil Soo Sung, Myeong Jun Song, Jung Hyun Kwon, Jeong Won Jang, Hee Yeon Kim

Zitieren

APA

Nam, H., Han, J. W., Lee, S. K., Yang, H., Lee, H. L., Sung, P. S., Song, M. J., Kwon, J. H., Jang, J. W., Chang, U. I., Kim, C. W., Nam, S. W., Bae, S. H., Choi, J. Y., Yoon, S. K., Yang, J. M., & Kim, H. Y. (2024). Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B. Journal of Gastroenterology and Hepatology. https://doi.org/10.1111/jgh.16593

Vancouver

Nam H, Han JW, Lee SK, Yang H, Lee HL, Sung PS, et al. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B. Journal of Gastroenterology and Hepatology. 2024. doi:10.1111/jgh.16593

BibTeX
@article{Nam2024,
  author = {Nam, Heechul and Han, Ji Won and Lee, Soon Kyu and Yang, Hyun and Lee, Hae Lim and Sung, Pil Soo and Song, Myeong Jun and Kwon, Jung Hyun and Jang, Jeong Won and Chang, U-Im and Kim, Chang Wook and Nam, Soon Woo and Bae, Si Hyun and Choi, Jong Young and Yoon, Seung Kew and Yang, Jin Mo and Kim, Hee Yeon},
  title = {Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patient with chronic hepatitis B},
  journal = {Journal of Gastroenterology and Hepatology},
  year = {2024},
  doi = {10.1111/jgh.16593}
}
Kostenlos starten →